Kiyomi Mashima, Morio Azuma, Ken Fujiwara, Takashi Inagaki, Iekuni Oh, Takashi Ikeda, Kento Umino, Hirofumi Nakano, Kaoru Morita, Kazuya Sato, Daisuke Minakata, Ryoko Yamasaki, Masahiro Ashizawa, Chihiro Yamamoto, Shin-Ichiro Fujiwara, Kaoru Hatano, Ken Ohmine, Kazuo Muroi, Nobuhiko Ohno, Yoshinobu Kanda
Acta histochemica et cytochemica 53(3) 43-53 2020年6月26日 査読有り
Leukemias are refractory hematopoietic malignancies, for which the development of new therapeutic agents requires in vivo studies using tumor-bearing mouse models. Although several organs are commonly examined in such studies to evaluate the disease course, the effectiveness of interventions and the localization of tumor cells in the affected organs are still unclear. In this study, we histologically examined the distribution of leukemia cells in several organs using two leukemic mouse models produced by the administration of two cell lines (THP-1, a human myelomonocytic leukemia, and A20, a mouse B cell leukemia/lymphoma) to severe immunodeficient mice. Survival of the mice depended on the tumor burden. Although A20 and THP-1 tumor cells massively infiltrated the parenchyma of the liver and spleen at 21 days after transplantation, A20 cells were hardly found in connective tissues in Glisson's capsule in the liver as compared with THP-1 cells. In the bone marrow, there was more severe infiltration of A20 cells than THP-1 cells. THP-1 and A20 cells were widely spread in the lungs, but were rarely observed in the small intestine. These findings suggest that each leukemia model has a unique localization of tumor cells in several affected organs, which could critically affect the disease course and the efficacy of therapeutic agents, including cellular immunotherapies.